Risk assessment and treatment of dyslipidemia in primary health care

Danish Medical Bulletin

Volumn 52, Issue 2, 2005, Pages 82-85

  Kanstrup, Helle ^a,b   Lassen, Jens Flensted ^a   Heickendorff, Lene ^a   Lauritzen, Torsten ^b   Larsen, Mogens Lytken ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL LABORATORY; CLINICAL PRACTICE; CONTROLLED STUDY; DIETARY INTAKE; DRUG USE; DYSLIPIDEMIA; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HIGH RISK POPULATION; HUMAN; INFORMATION SYSTEM; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT CARE; PATIENT COUNSELING; PATIENT MONITORING; PRESCRIPTION; PRIMARY HEALTH CARE; QUESTIONNAIRE; REGISTER; RISK ASSESSMENT;

ANTILIPEMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; COUNSELING; DENMARK; DYSLIPIDEMIAS; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS;

EID: 27244434618     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 1992; 45: 849-60.
2. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
4. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
7. Kanstrup H, Lassen JF, Heickendorff L, Larsen ML. The electronic laboratory information system, used for surveillance of routine practice for screeing and monitoring dyslipidemia. The international journal of Integrated Care 2001; 1: supplement, Abstract.
8. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569-82.
9. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
10. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-503.
11. Hallas J, Nissen A. Individualized drug utilization statistics. Analysing a population's drug use from the perspective of individual users. Eur J Clin Pharmacol 1994; 47: 367-72.
12. Sørensen HT. Regional administrative health registries as a resource in clinical epidemiology. International Journal of Risk and Safety in Medicine 1997; 10: 1-22.
13. Dansk selskab for almen medicin. Forebyggelse af iskæmisk hjertesygdom i almen praksis - med særligt henblik på dyslipidæmi. Ugeskr Laeger 1998; 160:(suppl 6).
14. Svilaas A, Risberg K, Thoresen M, Ose L. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol 2000; 86: 1250-3, A6.
15. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 1916-24.
16. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ. 1994; 308: 367-72.
17. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
18. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-504.